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Abstract
Background: Fecal calprotectin has been proposed as a non-invasive marker of intestinal inflammation in inflammatory
bowel disease in adults and children. Fecal calprotectin levels have been reported to be much higher in both healthy full-
term and preterm infants than in children and adults.
Objective: To determine the time course of fecal calprotectin (f-calprotectin) excretion in preterm infants from birth until
hospital discharge and to identify factors influencing f-calprotectin levels in the first weeks of life, including bacterial
establishment in the gut.
Methodology: F-calprotectin was determined using an ELISA assay in 147 samples obtained prospectively from 47 preterm
infants (gestational age, and birth-weight interquartiles 27–29 weeks, and 880–1320 g, respectively) at birth, and at 2-week
intervals until hospital discharge.
Principal Findings: Although median f-calprotectin excretion was 138 mg/g, a wide range of inter- and intra-individual
variation in f-calprotectin values (from day 3 to day 78) was observed (86% and 67%, respectively). In multivariate regression
analysis, f-calprotectin correlated negatively with ante and per natal antibiotic treatment (p=0.001), and correlated
positively with the volume of enteral feeding (mL/kg/d) (p=0.009), the need to interrupt enteral feeding (p=0.001), and
prominent gastrointestinal colonization by Clostridium sp (p=0.019) and Staphylococcus sp (p=0.047).
Conclusion: During the first weeks of life, the high f-calprotectin values observed in preterm infants could be linked to the
gut bacterial establishment.
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Introduction
Initially called leukocyte L1, calprotectin is a 36 kDa calcium
and zinc binding protein that constitutes about 60% of soluble
cytosol protein in human neutrophil granulocytes, and is found in
monocytes, macrophages and epithelial cells [1]. Calprotectin is
thought to regulate inflammatory processes [2], and exert
antimicrobial and anti-proliferative properties in vitro [3,4] and in
vivo [5]. Its resistance to proteolysis and stability even after a week
of storage at room temperature facilitate its determination in
faeces [6].
High fecal calprotectin (f-calprotectin) levels were shown to
correlate with an increased turnover of leukocytes in the intestinal
barrier and granulocyte migration towards intestinal lumen [7,8].
Hence, f-calprotectin has been proposed as a non-invasive marker
of intestinal inflammation in inflammatory bowel disease in adults
[9] and children [10]. A recent review points the relevance and
limitations of calprotectin determination in these clinical settings
[11].
F-calprotectin levels have been reported to be much higher
during the first few weeks of life both in healthy full-term [12–15]
and preterm infants [12,16–19] than in healthy adults [6] and
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calprotectin as a marker of gastrointestinal disease, particularly
necrotizing enterocolitis (NEC), has been explored in several
cohorts of preterm infants. However, due to the high inter- and
intra-individual variations consistently observed by all authors the
determination of a cutoff value for f-calprotectin has remained an
elusive goal, as cut-off values ranging from 200 to 2000 mg/g have
been proposed [16,18,21,22]. Although earlier studies have
assessed calprotectin concentrations in preterm infants, the factors
that affect its excretion in neonates are incompletely known and
remain controversial [12,16,17,19,22,23]. Earlier studies suggest f-
calprotectin is higher in infants born by cesarean section,
compared with vaginal delivery, and correlates positively with
postnatal age and volume of enteral feeds, and negatively with
antibiotic treatment. The latter factors are known to influence gut
bacterial colonization, suggesting a possible relationship between
bacterial establishment and calprotectin levels in neonatal period.
Accordingly, Mohan et al found that bifidobacterial supplemen-
tation was associated with a significant decrease in calprotectin
level [24].
In this context, it is of interest to improve our understanding of
factors influencing the f-calprotectin excretion in preterm infants.
The aims of the current study therefore were to describe the time
course of f-calprotectin excretion in preterm infants from birth
through hospital discharge, and to identify factors influencing its
fecal excretion during the first weeks of life, including bacterial
establishment in the gut.
Materials and Methods
Patients
Written, informed parental consent was obtained prior to
inclusion, according to protocols approved by the local Institu-
tional Review Board (Comite ´ de Protection des Personnes dans la
Recherche Biome ´dicale des Pays-de-la-Loire, Nantes, France).
Preterm infants enrolled in the current study were part of a larger
controlled trial on probiotic supplementation [25]. Preterm infants
admitted to the neonatal intensive care units at the Me `re-Enfant
Hospital (Nantes, France) and at the Institut de Pue ´riculture (Paris,
France) were eligible for enrolment in the prospective study if they
met the following inclusion criteria: a gestational age ,32 weeks, a
birth weight ,1500 g, a postnatal age no greater than 2 weeks,
and the absence of any disease other than those linked to
prematurity. Infants were fed with human milk and/or with a
preterm formula. They were randomly assigned to receive from
the start of enteral feeding until discharge from the NICU four
daily capsules of a supplement containing either (a) maltodextrin
alone (referred to as placebo group), or (b) 10
8 lyophilized cells per
unit of Lactobacillus rhamnosus GG (Valio, Ltd., USA) and
Bifidobacterium longum BB536 (Morinaga Milk Industry Co., Ltd.,
Japan) and maltodextrin (referred to as probiotic group).
Clinical data
Collected clinical parameters included gestational age, birth
weight, sex, mode of delivery (vaginal or cesarean section),
intrauterine growth retardation, 5-min Apgar score, maternal
treatment (corticoids and antibiotics). In addition, postnatal age,
type of enteral feeding (own mother’s milk, bank milk, or preterm
formula), postnatal treatment (antibiotics), volume of enteral
feeding (mL/kg/d), and number of enteral feeding interruptions
were recorded before each stool sample was collected. Poor
tolerance to enteral feeding was defined as a suspension of enteral
feeding for any day during the week following the day the fecal
sample had been obtained. After clinical assessment, enteral
feeding was interrupted if there were significant residues in gastric
aspirates, abdominal distension, and/or blood in stool. As enteral
feeding is routinely suspended when ibuprofen is administered (to
promote the closure of ductus arteriosus), the planned, on purpose
interruptions of enteral feeding motivated by the prescription of
ibuprofen treatment, were not considered as an event of poor GI
tolerance.
Stool collection
Stool collection was performed on the first 24 infants enrolled in
each neonatology unit for the follow-up of fecal microbiota and
fecal calprotectin. Stool samples were collected weekly from
diapers in two sterile plastic tubes until hospital discharge. One of
the tubes contained 0.5 mL of brain heart infusion (BHI) with
15% glycerol as a cryoprotective agent for microbiota analysis. All
fecal samples were frozen and stored at -80uC immediately after
collection until analysis.
Microbiological analysis of fecal samples
Fecal microbiota was analyzed weekly. After thawing the
samples collected in BHI, serial dilutions were performed, and
spread using the automatic spiral system (Chemunex-AES
Laboratoire, Bruz, France) on various media allowing the isolation
of the main genera found in preterm infants’ fecal microbiota, i.e.
staphylococci, enterococci, enterobacteria, lactobacilli, clostridia,
Bacteroides, and bifidobacteria, as previously described [26].
Bacterial counts were expressed as the log10 CFU/g of feces and
the count threshold was 3 log10 CFU/g of feces. Bacterial
identification was performed at the species level using routine
laboratory methods and Wadsworth laboratory procedures for
anaerobes [27]. Moreover, for bifidobacteria, identification of
genus Bifidobacterium was performed by genus PCR [28], and
species determination using 16S rRNA gene sequencing. The 2
probiotic strains were detected specifically by a culture-polymerase
chain reaction method.
Fecal calprotectin determination
Before analysis, frozen stool samples were thawed at room
temperature. Fecal calprotectin concentrations were determined in
duplicate at 2-week intervals, using a commercial enzyme linked
immunoassay (CalprestH, Eurospital, Trieste, Italy). The mean
coefficient of variation was less than 3%.
Statistical analysis
Statistical analysis was performed using SPSSH version 14.0
(SPSS, Chicago, IL). Results are reported as median and
interquartiles, and percentages were presented as percent [95%
confidence interval]. Chi2 and Mann-Whitney U test were used to
compare proportion and quantitative values respectively. Spear-
man’s correlation test was used to evaluate the relationship
between selected perinatal or neonatal characteristics and fecal
calprotectin values. All variables that showed a statistically
significant correlation with fecal calprotectin by univariate analysis
were subsequently analyzed together in forward and backward
stepwise, multivariate regression analyses, after log transformation
of fecal calprotectin values. Statistically significant differences were
assumed when p,0.05.
Results
Patients
Forty-seven preterm infants (29 boys and 18 girls) were enrolled
in the current study. They had a median gestational age of 29
weeks [interquartile, 27–29 weeks], a median birth-weight of
Calprotectin in Preterm
PLoS ONE | www.plosone.org 2 June 2010 | Volume 5 | Issue 6 | e110831100 g [interquartile, 880–1320 g]. Sixteen were born by
caesarean section and 31 by vaginal delivery. Median Apgar
score at 5 minutes was 10 [interquartile, 8–10]. During follow-up,
17 infants were fed solely with human milk, 29 with human milk
combined with a preterm infant formula, and 1 with a preterm
infant formula. As this study was part of a larger clinical trial on
probiotic supplementation, 25 of the 47 infants received a milk
supplemented with the probiotic strains from the start of enteral
feeding (median: 2 days of life, [interquartile, 2–4]) until discharge
from hospital (median: 62.5 days of life, [interquartile, 45.5–78.5]).
The median time [interquartile] to full enteral feeding (100% of
total calories supplied via the enteral route) was 20.0 days
[interquartile, 14.5–30.0]. Twenty-five of the 47 infants were born
from mothers who received antibiotics (12 during the two last
month of pregnancy, 7 during delivery and 6 during both), 39
received antibiotics due to a materno-fetal infection (median
duration: 2 days, [interquatile, 2–3]) and 25 received antibiotics
due to a nosocomial infection (mean [SD] cures: 2.7 [0.8]; median
cumulated duration: 15.1 days, [interquartile: 9–20]). The
antibiotics included broad-spectrum cephalosporins, penicillins 6
b-lactamase inhibitors, glycopeptides, and/or aminosides used
either alone or in combination.
Gut bacterial establishment
The data from culture-based analyses showed that gastrointes-
tinal tract of all infants was poorly colonized, harbouring no more
than seven bacterial species (Table 1). The most common bacteria
isolated were staphylococci (Table 1). In contrast, colonization by
enterococci occurred in only one third of infants at a low level and
enterobacteria were isolated in 23 infants. With regard to
anaerobes, Bacteroides was isolated in only one infant whereas
clostridia were isolated in one half of infants. Lactobacilli and
bifidobacteria, which were identified as the two probiotic strains
were found in 26 and 21 infants, respectively.
Fecal calprotectin concentrations
Throughout follow-up (from day 3 to day 78), a total number of
147 fecal samples were obtained, with an average of 3 samples per
infant. The median fecal calprotectin level calculated on all 147
samples was 138 mg/g of feces [interquartile, 58–271 mg/g],
ranging between 15 and 811 mg/g. A wide range of calprotectin
levels were observed, with inter- and intra-individual coefficients of
variation of 86% and 67%, respectively. Fecal calprotectin levels
were not significantly different in the placebo and probiotic groups
throughout the study (p=0.31) [25]. There was no effect of center,
as median calprotectin levels were 180 mg/g [interquartile 52–
283], and 117 mg/g [interquartile 65–234] in centers 1 and 2,
respectively (NS).
The first initial fecal samples were obtained at 11 days of life
(n=47, [interquartile, 7–15 days of life]) and the median fecal
calprotectin levels were 87 mg/g [interquartile, 35–153 mg/g]. In
these fecal samples, fecal calprotectin levels was not affected by
gender (p=0.39), nor the use of corticoids ante partum (p=0.66), or
the mode of delivery (p=0.37). In contrast, fecal calprotectin levels
were significantly lower in infants whose mothers had received
antibiotics ante and per partum (n=25), compared with infants who
did not receive antenatal antibiotics (n=22)(median: 58 mg/g,
[interquartile, 31–106 mg/g vs. median: 132 mg/g, [interquartile,
86–227 mg/g]; p=0.005). Otherwise, there was no statistically
significant correlation between fecal calprotectin levels and birth-
weight (r=0.08, p=0.59), nor gestational age (r=0.09, p=0.55),
or intrauterine growth evaluated by birth weight Z-score (r=0.16,
p=0.29).
The second set of samples were obtained in 43 infants at a
median age of 23 days [interquartile, 20–28 days of life], the third
set of sample were obtained in 22 infants at a median age of 37
days [interquartile, 34–42 days of life], and the fourth one from 9
infants at a median age of 56 days [interquartile, 46–65 days of
life]. When considering the entire set of 147 fecal samples obtained
in univariate analysis, fecal calprotectin levels were significantly
lower in infants whose mothers had received antibiotics ante and per
partum (n=74), compared with infants who had not received any
antenatal antibiotic treatment (n=73)(median: 94 mg/g, [inter-
quartile, 41–225 mg/g] vs. median: 183 mg/g, [interquartile, 94–
320 mg/g]; p=0.002) (Fig 1). Likewise, fecal calprotectin levels
were significantly lower in infants with postnatal antibiotherapy
(n=35), compared with infants without postnatal antibiotherapy
(n=112)(median: 97 mg/g, [interquartile, 32–206 mg/g] vs. medi-
an: 155 mg/g, [interquartile, 77–298 mg/g]; p=0.001). Otherwise,
fecal calprotectin levels found in infants who had received enteral
feeding the day prior to sampling (n=125) were not significantly
different from those who had not been fed enterally the day before
(n=22)(median: 147 mg/g, [interquartile, 71–268 mg/g] vs. medi-
an: 113 mg/g, [interquartile, 32–283 mg/g]; p=0.50).
Among infants receiving enteral feeding the day before
sampling, fecal calprotectin levels were significantly higher in
infants who received formulas as their exclusive or predominant
Table 1. Bacterial colonization in enrolled preterm infants from week 1 to week 6.
Weeks 1–2 (n=43)
a Weeks 3–4 (n=39) Weeks 5–6 (n=22)
Aerobic genera
Staphylococci 41 (95%)
b 7.4 (3.3–8.8)
c 39 (100%) 7.3 (3.8–9.5) 21 (95%) 6.9 (3.8–8.2)
Enterococci 5 (12%) 5.3 (3.3–8.8) 11 (28%) 6.1 (3.9–9.0) 9 (41%) 6.5 (4.7–10.1)
Enterobacteria 14 (33%) 8.4 (3.3–9.5) 21 (54%) 8.8 (3.3–10.0) 13 (59%) 8.5 (5.0–9.2)
Lactobacilli 23 (53%) 7.4 (3.3–9.0) 26 (67%) 7.1 (3.6–9.4) 14 (64%) 6.1 (3.6–8.7)
Anaerobic genera
Bacteroides 1 (2%) 8.4 1 (3%) 6.1 1 (5%) 6.6
Clostridium 11 (26%) 5.9(3.3–9.0) 22 (56%) 6.9 (3.3–8.2) 13 (59%) 6.0 (4.1–7.5)
Bifidobacteria 16 (37%) 6.2 (3.3–9.1) 14 (36%) 5.7 (3.3–10.0) 9 (41%) 4.8 (3.3–8.4)
anumber of analyzed infants.
bnumber of colonized infants (%).
cbacterial counts expressed as log10 CFU/g of feces (median, range) in colonized infants, threshold =3.0.
doi:10.1371/journal.pone.0011083.t001
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(median: 226 mg/g [interquartile, 116–334 mg/g] vs. median:
126 mg/g [interquartile, 55–237 mg/g]; p=0.02), and were
significantly higher in infants with poor tolerance to enteral
feeding (n=7) than infants with good tolerance to enteral feeding
(n=118) (median: 285 mg/g, [interquartile, 208–552 mg/g] vs.
median: 132 mg/g, [interquartile, 62–260 mg/g]; p=0.008) (Fig 2).
By the calculation of the receiver operator curve (ROC), a cut-off
level of 205 mg/g of feces was defined for the detection of poor
tolerance in preterm infants and area under the ROC curve was
0.8060.06 (p=0.08). A fecal calprotectin levels more than
200 mg/g has a good sensibility of 1.0 [0.72–1.0] but a low
specificity of 0.64 [0.57–0.71] to predict poor tolerance to enteral
feeding.
Among the 147 fecal samples analyzed, fecal calprotectin levels
were positively correlated with the volume of enteral feeding (mL/
Kg/day) (r=+0.36, p=0.01), postnatal age (r=+0.17, p=0.036)
and postconceptional age (r=+0.34, p=0.001), and negatively
correlated with weight gain (expressed in weight Z-score
gain)(r=20.19, p=0.03).
In the samples analyzed by culture methods (n=128), there
were significant positive correlations between fecal calprotectin
levels and intestinal colonization levels by Staphylococcus (r=+0.18,
p=0.04), Enterococcus (r=+0.19, p=0.03) and Clostridium
(r=+0.22, p=0.011). In contrast, no significant correlations were
found between fecal calprotectin levels and enterobacteria
(r=+0.12, p=0.15), nor Bifidobacterium (r=+0.11, p=0.19).
Nevertheless, fecal calprotectin levels and Lactobacillus tended to
be positively correlated (r=+0.17, p=0.06).
In multivariate regression analysis, fecal calprotectin correlated
negatively with ante and per natal antibiotic treatment (p=0.001),
and correlated positively with the volume of enteral feeding (mL/
kg/d) (p=0.009), the need to interrupt enteral feeding (p=0.001),
and prominent gastrointestinal colonization by Clostridium sp
(p=0.019) and Staphylococcus sp (p=0.047) (Table 2).
Discussion
The findings of the current study confirm that fecal calprotectin
levels are elevated in premature infants, compared with older age
groups, with a wide range of inter- and intra-individual variation
during the first few weeks of life. They further demonstrate that the
most significant factors that affect calprotectin excretion are ante
and per natal antibiotic treatment, volume of enteral feeding
Figure 1. Fecal calprotectin levels in preterm infants with or without antenatal antibiotherapy. The boxplot shows the median (central
horizontal line) and includes the 25
th (lower box border) to 75
th percentile (upper box border) of fecal calprotectin (mg/g of feces) in preterm infants
with (74 fecal samples) and without (73 fecal samples) antenatal antibiotherapy following the postconceptional age (weeks).
doi:10.1371/journal.pone.0011083.g001
Figure 2. Fecal calprotectin levels in preterm infants without or
with poor tolerance to enteral feeding. Fecal calprotectin in
preterm infants without poor tolerance to enteral feeding (i.e. with
unplanned enteral feeding interruption, n=118), and with poor
tolerance to enteral feeding (i.e. with unplanned enteral feeding
interruption, n=7). The boxplot shows the median (central horizontal
line) and includes the 25
th (lower box border) to 75
th percentile (upper
box border). Dotted line represents cut-off level (205 mg/g of feces) for
poor tolerance to enteral feeding (see text for details).
doi:10.1371/journal.pone.0011083.g002
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feeding, and the gastrointestinal bacterial colonization.
Consistent with previous studies [12,16–18], the fecal calpro-
tectin levels observed in healthy preterm infants in the current
study were high and clearly exceed those reported in healthy
adults and children. Likewise, we observed a wide range of inter-
and intra-individual variation. Such range of variation is unlikely
to result from a poor stability of calprotectin in stools, since
calprotectin resists proteolysis, and is stable at room temperature
for up to a week [29]. Although stool samples were collected from
babies’ diapers in the current study (as in all studies carried out in
infants), the sampling technique cannot account for the variation
either, since the changes in calprotectin concentrations found in
the current study largely exceed what could be accounted for by
water absorption [14]. Besides, the changes observed cannot arise
from the ingestion of calprotectin present in human milk, since, in
agreement with earlier findings [14], none of the human milk
samples we analyzed (n=10, data not shown) contained any
detectable calprotectin (threshold: 15 mg/L). Thus, the wide
range of f-calprotectin values may reflect true inter- and intra-
individual variability in calprotectin fecal excretion in that patient
population.
The high calprotectin levels observed in neonates may reflect
the increased transepithelial migration of neutrophil granulocytes
and/or macrophages into the intestinal lumen of preterm infants.
As Berstad et al reported a significant correlation between
calprotectin levels in gut lavage fluid and intestinal permeability
[8], the increased migration of neutrophil granulocytes and/or
macrophages into the gut lumen might be related to the higher
intestinal permeability associated with intestinal mucosal immatu-
rity. However, f-calprotectin levels are similar in preterm and full
term infants, although intestinal permeability is higher in preterm
than in term infants [30].
In univariate analysis, levels of calprotectin in the initial samples
did not correlate with gestational age, birth weight or the mode of
delivery, supporting earlier reports [16,17]. Although other
authors found a correlation of calprotectin with gestational age,
the latter correlation was found with early determination in
meconium, whereas calprotectin levels subsequently decreased
during the first week postnatal [16,19]. Likewise, we found no
significant correlation between f-calprotectin and type of feeding
(formulas as exclusive or predominant source of feeding vs. human
milk) in univariate analysis, consistent with other studies [16–18].
By contrast, gut microbiota appeared to influence calprotectin
excretion in the present cohort, as suggested by Josefsson et al [16].
In the current study gut microbiota was analyzed by culture,
which allowed the isolation and identification of the main bacterial
genera, even in a sub-dominant status. A limitation of this
approach could be the inability to detect the uncultivable part of
the microbiota. However, by contrast with adult gut microbiota,
the latter accounts for a very small fraction of the overall bacterial
population in preterm neonates [31,32]. We found correlations
between f-calprotectin and both microbiota per se, and other
factors known to influence gut bacterial establishment as well. The
current report thus is first to provide evidence for an effect of
intestinal bacterial colonization on fecal calprotectin excretion
Three lines of evidence point to such effect. First in both univariate
and multivariate analyses, f-calprotectin correlated positively with
intestinal colonization by Staphylococcus and Clostridium. Secondly, in
univariate analysis, fecal calprotectin levels correlated positively
with postnatal and postconceptional ages, factors known to
influence the gut microbiota composition. However, this correla-
tion did not remain significant in multivariate analysis in
accordance with Campeotto et al [17], as opposed to the study
by Josefsson et al [16]. Thirdly, the use of antibiotics impacted f-
calprotectin levels. Indeed, throughout the study f-calprotectin
correlated negatively with ante and per natal antibiotics in
univariate and multivariate analyses. To our knowledge, the
current study is first to demonstrate such impact. Indeed, earlier
studies have shown changes in the gut microbiota establishment in
infants born from mothers who had received antibiotic per partum
[33]. Likewise, a negative correlation was found with neonatal
antibiotic courses in univariate analysis, but in contrast to other
studies [16] this correlation did not remain significant in
multivariate analysis. However, in the latter study a correlation
was only observed in infants treated with cefotaxim and
meropenem, two broad-spectrum antibiotics.
To summarize, factors known to delay gut bacterial colonization
(both ante- and post-natal antibiotic treatments) correlated
negatively with fecal calprotectin levels, whereas factors known
to favor gut bacterial colonization (gestational age and post-
conceptional age) correlated positively with fecal calprotectin
levels. This is in accordance with the study of Mohan et al, who
described a decrease in f-calprotectin levels in infants supplement-
ed with a probiotic strain [24]. In the latter study, probiotic
supplementation increased bifidobacteria levels, and decreased the
levels of clostridia, a genus positively correlated in with f-
calprotectin in the current study. By contrast, a recent study did
not find any correlation between gut microbiota colonization and
f-calprotectin: however, the culture techniques used in that report
did not allow detection of clostridia [23].
Otherwise, we observed a highly significant, positive correlation
between the volume of enteral feeding (mL/Kg/day) and f-
calprotectin excretion in multivariate analysis, as previously
reported [16].
Taken together, the current results suggest that exposure to two
kinds of luminal ‘antigens’2i.e, commensal intestinal bacteria, and
dietary antigens2 might induce a state of ‘‘physiological’’
Table 2. Main explanatory variables found by multivariate analysis for fecal calprotectin values.
Variables Non standardized coefficient Standardized coefficient p-value
(R
2=0.32, n=125)
Ante/per natal antibiotic treatment (yes/no) 20.558 20.276 0.001
Volume of enteral feeding (mL/Kg/d) +0.004 +0.236 0.009
Unplanned interruptions of enteral feeding (yes/no) +0.920 +0.257 0.001
Clostridium (.10
5 CFU/g of feces) (yes/no) +0.468 +0.206 0.019
Staphylococcus (.10
5 CFU/g of feces) (yes/no) +0.347 +0.206 0.047
doi:10.1371/journal.pone.0011083.t002
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full-term infants. It is tempting to speculate that intestinal bacteria,
and specific, individual components of the commensal microbiota
might have variable abilities to stimulate transepithelial granulo-
cyte migration and/or to induce calprotectin release from
leucocytes and macrophages, as shown in gnotobiotic piglets
colonized with various strains of Escherichia coli [34]. Thus, the
stress induced by birth per se and by the adaptation to the extra-
uterine life, particularly concerning gut bacterial colonization,
rather than the degree of mucosal maturation or term of birth,
may account for the higher fecal calprotectin levels found in
infants, compared to older age groups. This high intestinal
expression of calprotectin, known to display antimicrobial
properties, might participate in the mechanisms of defense in
neonates, whose intestinal immune system is not mature.
Despite these ‘‘physiological’’ high levels of f-calprotectin,
several studies strongly suggest that a rise in f-calprotectin above
this high, baseline levels may be a candidate, non-invasive marker
of gastrointestinal diseases, in particular NEC [16–18,21,22].
These studies reported a significant rise in f-calprotectin levels in
infants suffering from gastrointestinal disease, particularly from
NEC. Several thresholds for suspicion of NEC have been
proposed, i.e. 200mg/L in Caroll’s study [22], 2000 mg/g in the
study by Josefsson [16], and 636 mg/g for the study by Campeotto
et al [21]. The threshold in Caroll’s study appears too low. Indeed,
the latter study, performed in a very small group of infants (6
infants with NEC, and 6 healthy controls), reported low f-
calprotectin values in healthy preterm infants as compared with
the literature. In our study, we did not observe any case of NEC,
and median f-calprotectin excretion was 138 mg/g [interquartile,
58–271 mg/g]. Using the three thresholds reported among the
infants in our cohort 34 infants should have been suspected of
having NEC using Caroll’s threshold, 0 with Josefsson’s cut-off,
and 3 with Campeotto’s threshold. The rise in calprotectin levels
we observed in cases of intolerance to enteral feeding suggests the
monitoring of f-calprotectin might be useful as a warning signal for
gastrointestinal disease and/or poor tolerance of enteral nutrition.
However, the lack of specificity we observed might be due to the
‘‘physiological inflammation’’ linked to the bacterial colonization.
Many more studies with much larger cohorts are warranted to
confirm whether such thresholds or cut-off values could be
recommended for routine use in clinical practice.
Finally, it may seem paradoxical to observe that a rise in
calprotectin is observed in parallel with increased volume of
enteral feeding, but a rise is also observed when there is a need to
interrupt enteral feeding, i.e., in cases of poor digestive tolerance.
To further address this issue we divided samples according to the
terciles of enteral feeding volume received, and, within each
tercile, we separated samples depending on the need to interrupt
enteral feeding or not. As shown in Fig 3, on one hand,
calprotectin tends to be higher for the upper tercile of enteral
feeding volume: this is consistent with the fact that calprotectin
increases with enteral volume. On the other hand, for any given
tercile of enteral volume administered, calprotectin was higher
when feeding intolerance occurred. Should we have very large
numbers of feeding interruptions within each tercile, we might be
able to define ‘safe’ levels of calprotectin for a given volume of
feeding. Interestingly, all instances when feeding had to be
interrupted were associated with a calprotectin level .205 mg/g.
This is consistent with the good sensitivity of calprotectin, yet this
cutoff level has a poor specificity as well, as discussed with the
ROC curve (see above).
In conclusion the current study demonstrates for the first time
that calprotectin excretion can be linked to the gut bacterial
establishment. We speculate that the enhanced expression of this
protein possessing many potential functions including antimicro-
Figure 3. Fecal calprotectin as a function of the tercile of enteral feeding volume and tolerance to enteral feeding. The median and
interquartile range of fecal calprotectin are plotted for each volume of enteral feeding in infants with good (open boxes) or poor (closed boxes)
tolerance to feeding. Poor tolerance to feeding was defined as the need for unplanned enteral feeding interruption.
doi:10.1371/journal.pone.0011083.g003
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thus be of benefit for the developing gut in both full term and
premature infants. Clinical situations may therefore occur when a
pathological rise in calprotectin might be offset by a physiological
increase.
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